Why Co-Diagnostics Stock Is Trading Higher Today

Co-Diagnostics CODX shares are trading higher on Thursday after the company announced its Logix Smart ABC Test is anticipated to be ready for launch to U.S. CLIA laboratory customers the first week of October.

Co-Diagnostics is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). 

Co-Diagnostics shares were trading up 5.58% at $14.20 at the time of publication. The stock has a 52-week high of $30.99 and a 52-week low of 85 cents.